Skip to main content
Access Resources

MJFF Publications

The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.

From
To
  • Default content image

    LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits


  • Default content image

    The Michael J. Fox Foundation’s Efforts to Develop New Tools for Understanding LRRK2 Biology and the Role of LRRK2 in Parkinson’s Disease Pathology

    As the greatest known genetic contributor to Parkinson's disease (PD), the leucine-rich repeat kinase 2 (LRRK2) gene and protein are targets of interest for Parkinson’s disease research and…

  • Default content image

    The Michael J. Fox Foundation’s Efforts to Understand the Relationship between GBA1 and Alpha-Synuclein through the Development and Characterization of Preclinical Models

    Heterozygous mutations in the GBA1 gene--which encodes for lysosomal glucocerebrosidase (GCase)--are the most common genetic risk factor for Parkinson’s disease (PD). In addition, decreased GCase…

  • Default content image

    Characterization of a humanized A53T alpha-synuclein (aSyn A53T KI) and alpha-synuclein KO (aSyn KO) models

    Mutations and multiplications in the SNCA gene encoding the alpha-synuclein protein are linked to an autosomal dominant form of Parkinson’s disease (PD). One such mutation is the alanine-to-threonine…

  • Default content image

    The Michael J. Fox Foundation’s Strategy to Generate, Characterize, and Distribute Preclinical Antibody Tools for Investigating Rab Molecular Biology

    A field-wide challenge in Parkinson’s disease (PD) research is a general lack of availability for high-quality, reproducible, and readily accessible preclinical research tools. To address these…

  • Default content image

    LRRK2 Detection in PBMC Consortium

    The “LRRK2 Detection in PBMC Consortium” is a pre-competitive collaboration between MJFF and select industry partners with the goal of optimizing the measurement of pLRRK2 in human PBMCs. MJFF…

  • Default content image

    Cell Line Resources from Parkinson’s Progression Markers Initiative (PPMI) Participants

    The Parkinson’s Progression Markers Initiative (PPMI) is a longitudinal observational study conducted at over thirty international sites that collects data and biospecimens from idiopathic Parkinson…

Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.

From
To
  • Default content image

    Alpha-Synuclein: A Therapeutic Target and Potential Biomarker in Parkinson's Disease

    A detailed discussion of our current understanding of alpha-synuclein biology and the ongoing research and development surrounding its role in Parkinson's disease.

  • Default content image

    Diagnosis and Management of Neurodegenerative Atypical Parkinsonism

    A detailed consideration of the neurodegenerative diseases that can cause parkinsonism including dementia with Lewy bodies (DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP)…

  • Default content image

    Deep Brain Stimulation and Magnetic Resonance-guided Focused Ultrasound

    A review of innovations in surgical Parkinson's disease treatments, inlcuding deep brain stimulation and magnetic resonance-guided focused ultrasound.

  • Default content image

    Dystonia and Parkinson's Disease

    An exploration of the various manifestations of dystonia in the context of Parkinson's disease.

  • Default content image

    Levodopa 2.0: New Strategies to Even Out the Peaks and Valleys

    A discussion on the latest in new formulations and supplemental therapies of levodopa.

  • Default content image

    Dementia with Lewy Bodies: In the News and in the Clinic

    A practical review of the diagnosis and management of dementia with Lewy bodies.

Michael J. Fox Foundation publications supported through our OAP program.

We believe that the results of all MJFF-funded research should be promptly published and broadly disseminated to accelerate innovation and foster collaboration toward our shared goal of new treatments and cures for Parkinson’s disease. 

Request open access coverage funds for your MJFF project here

From
To
  • Default content image

    The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models

    Abstract Heterozygous mutations in the GBA1 gene-encoding lysosomal glucocerebrosidase (GCase)--are the most common genetic risk factor for Parkinson's disease (PD). Experimental evidence suggests a…

  • Default content image

    Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease

    Abstract Background: There is growing interest in health-related quality of life (HRQOL) as a comprehensive view of the patient's well-being, guiding concept for the treating clinician, and…

  • Default content image

    Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages

    Abstract Leucine-rich-repeat kinase 2 (LRRK2), a potential therapeutic target for the treatment of Parkinson's disease (PD), is highly expressed in monocytes and macrophages and may play a role in…

  • Default content image

    Isogenic human SNCA gene dosage induced pluripotent stem cells to model Parkinson's disease

    Abstract Alpha-synuclein overexpression and aggregation are critical factors in the pathogenesis of Parkinson's disease (PD). Clinical cases with alpha-synuclein (SNCA) multiplications or deletions…

  • Default content image

    Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2

    Abstract Mutations in the gene coding for leucine-rich repeat kinase 2 (LRRK2) are a leading cause of the inherited form of Parkinson’s disease (PD), while LRRK2 overactivation is also associated…

  • Default content image

    Designing the Fostering Inclusivity in Research Engagement for Underrepresented Populations in Parkinson's Disease study

    Abstract Background: Population reflective research enrollment improves study generalizability and disease knowledge. Nevertheless, the proportion of underrepresented groups (URGs) in Parkinson's…

  • Default content image

    Plasma Metabolite Signature Classifies Male LRRK2 Parkinson's Disease Patients

    Abstract Parkinson's disease (PD) is a progressive neurodegenerative disease, causing loss of motor and nonmotor function. Diagnosis is based on clinical symptoms that do not develop until late in…

Female researcher pipetting in lab.

Breaking Research Updates

Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.

Read Research News
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.